For the treatment of patients with HCV-HIV-1 coinfection: the recommendations are the same as listed above. For patents with genotype 1 HCV who are not eligible to receive interferon: sofosbuvir plus ribavirin for 24 weeks can be considered. For patients with HCV and hepatocellular carcinoma awaiting liver transplantation: sofosbuvir plus ribavirin for a duration of up to 48 weeks or until liver transplantation, whichever occurs first. Simeprevir in Combination with Sofosbuvir for HCV Infection: for details see the Simeprevir Drug Summarypage and Simeprevir Full Prescribing Information Daclatasvir in Combination with Sofosbuvir for HCV Infection: for details see the Daclatasvir Drug Summarypage and Daclatasvir Full Prescribing Information

Brand name:Sovaldi

Active Ingeridents:Sofosbuvir

Company Name: Gilead

Package: 28 tabs/bottle

Strength : 400 mg

Mechanism of action:

Sofosbuvir is a prodrug using the ProTide biotechnology strategy. It is metabolized to the active antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate. The triphosphate serves as a faulty substrate for the NS5B protein, which is the viral RNA polymerase, accordingly goes about as an inhibitor of viral RNA combination.In spite of the fact that sofosbuvir has a 3’ hydroxyl gathering to go about as a nucleophile for an approaching NTP, a comparative nucleotide simple, 2’- deoxy-2’- α-fluoro-β-C-methylcytidine, is proposed to go about as a chain eliminator on the grounds e causes a steric clash with an incoming NTP. Sobosbuvir would act in a similar way. Before the disclosure of sofosbuvir, an assortment of nucleoside analogs had been analyzed as antihepatitis C medicines, yet these showed moderately low power. This low intensity emerges to a limited extent in light of the fact that the enzymatic expansion of the first of the three phosphate gatherings of the triphosphate is moderate. The plan of sofosbuvir, in light of the protide approach, stays away from this moderate stride by building the main phosphate aggregate into the structure of the medication amid union. Extra gatherings are appended to the phosphorus to briefly veil the two negative charges of the phosphate assemble, accordingly encouraging passage of the medication into the contaminated cell. The NS5B protein is a RNA-subordinate RNA polymerase basic for the viral multiplication cycle. Sofosbuvir and other nucleotide inhibitors of the HCV RNA polymerase exhibit a very high barrier to resistance development. This is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid resistance development has proved to be an important cause of therapeutic failure.

The recommended daily dose of Sovaldi (Sofosbuvir) is 400mg tablet to be taken once daily with or without food. Sovaldi (Sofosbuvir) should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC (Chronic Hepatitis C) in adults. It is highly advisable to administer the drug under strict medical supervision and advice.

Store:

Store at 25°C in a dry place.

Side effects:

The following serious adverse reactions are described below and elsewhere in the labeling:

* Serious Symptomatic Bradycardia When Coadministered with Amiodarone and Another HCV Direct Acting Antiviral [see WARNINGS AND PRECAUTIONS]. Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. When SOVALDI is administered with ribavirin or peginterferon alfa/ribavirin, refer to the respective prescribing information for a description of adverse reactions associated with their use.

Precaution:

Safety and efficacy have not been established in patients younger than 18 years. Consult WARNINGS section for additional precautions.

Warning:

Sovaldi (Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Hepcinat

Indication:

It is used for the treatment of hepatitis Cvirus (HCV) infection. It has been marketed since 2013. Compared to previous treatments, Sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy. Hepcinat(Sofosbuvir) allows most patients to be treated successfully without the use of peginterferon, an injectable drug with severe side effects. that is a key component of older drug combinations for the treatment of HCV. Hepcinat(Sofosbuvir) is used for the treatment of chronic hepatitis C, genotypes 1, 2, 3, and 4, in combination with pegylated interferon and ribavirin, or with ribavirin alone. It is also used in combination with the viral NS5a inhibitor ledipasvir in an interferon-free combination for the treatment of genotype 1 hepatitis C infection. Hepcinat(Sofosbuvir) is also used in HCV patients with an HIV coinfection. The treatment is based on a number of clinical trials, for example the ELECTRON trial which showed that a dual interferon-free regimen of Sofosbuvir plus ribavirin produced a 24-week post-treatment sustained virological response (SVR24) rate of 100% for previously untreated patients with HCV genotypes 2 or 3.

Brand name: Hepcinat

Active Ingeridents: Sofosbuvir

Company Name: Natco

Package: 28 Tablets

Strength : 400 mg

Mechanism of action:

Hepcinat(Sofosbuvir) contains oral nucleotide analog inhibitor of the hepatitis C virus (HCV) polymerase. The drug is a direct-acting antiviral agent and interferes straight with the HCV lifecycle, restraining the viral replication. It can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. The drug is available for oral use in the form of 400mg tablets.

Dosage and Administration:

The recommended daily dose of Hepcinat(Sofosbuvir) is 400mg tablet to be taken once daily with or without food. Hepcinat(Sofosbuvir) should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC (Chronic Hepatitis C) in adults. It is highly advisable to administer the drug under strict medical supervision and advice.

Store:

Store at 25°C in a dry place.

Side effects:

Adverse events associated with the use of Hepcinat(Sofosbuvir) in combination with Ribavirin may include, but are not limited to, the following

* Fatigue , headache Adverse events associated with the use of Hepcinat(Sofosbuvir) in combination with Peginterferon Alfa and Ribavirin may include, but are not limited to, the following:

* Fatigue,headache, nausea, insomnia, anemia

Precaution:

Safety and efficacy have not been established in patients younger than 18 years. Consult WARNINGS section for additional precautions.p>

WARNING:

Hepcinat (Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Sofovir

Indication:

It is used for the treatment of hepatitis Cvirus (HCV) infection. It has been marketed since 2013. Compared to previous treatments, Sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy. Sofovir (Sofosbuvir) allows most patients to be treated successfully without the use of peginterferon, an injectable drug with severe side effects. that is a key component of older drug combinations for the treatment of HCV. Sofovir (Sofosbuvir)is used for the treatment of chronic hepatitis C, genotypes 1, 2, 3, and 4, in combination with pegylated interferon and ribavirin, or with ribavirin alone. It is also used in combination with the viral NS5a inhibitor ledipasvir in an interferon-free combination for the treatment of genotype 1 hepatitis C infection. Sofovir (Sofosbuvir) is also used in HCV patients with an HIV coinfection. The treatment is based on a number of clinical trials, for example the ELECTRON trial which showed that a dual interferon-free regimen of Sofosbuvir plus ribavirin produced a 24-week post-treatment sustained virological response (SVR24) rate of 100% for previously untreated patients with HCV genotypes 2 or 3.

Brand name: Sofovir

Active Ingeridents: Sofosbuvir

Company Name:Hetero

Package: 28 Tablets

Strength : 400 mg

Mechanism of action:

Sofovir (Sofosbuvir) contains oral nucleotide analog inhibitor of the hepatitis C virus (HCV) polymerase. The drug is a direct-acting antiviral agent and interferes straight with the HCV lifecycle, restraining the viral replication. It can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. The drug is available for oral use in the form of 400mg tablets.

Dosage and Administration:

The recommended daily dose of is 400mg tablet to be taken once daily with or without food. Sofovir (Sofosbuvir) should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC (Chronic Hepatitis C) in adults. It is highly advisable to administer the drug under strict medical supervision and advice.

Store:

Store at 25°C in a dry place.

Side effects:

Adverse events associated with the use of Sofovir (Sofosbuvir) in combination with Ribavirin may include, but are not limited to, the following

* Fatigue , headache Adverse events associated with the use of Sofovir (Sofosbuvir) in combination with Peginterferon Alfa and Ribavirin may include, but are not limited to, the following:

* Fatigue,headache, nausea, insomnia, anemia

Precaution:

Safety and efficacy have not been established in patients younger than 18 years. Consult WARNINGS section for additional precautions.

WARNING:

Sofovir (Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Myhep

Indication:

MyHep contains the active ingredient Sofosbuvir. It is a generic brand of anti-viral medication used to treat Hepatitis C virus. MyHep is manufactured by Mylan Pharmaceuticals. Sofosbuvir can help the immune system and the liver recover from an Hepatitis C infection.

Brand name: Myhep

Active Ingeridents: Sofosbuvir

Company Name: Mylan

Package: 28 Tablets

Strength : 400 mg

Mechanism of action:

Myhep(Sofosbuvir) contains oral nucleotide analog inhibitor of the hepatitis C virus (HCV) polymerase. The drug is a direct-acting antiviral agent and interferes straight with the HCV lifecycle, restraining the viral replication. It can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. The drug is available for oral use in the form of 400mg tablets.

Dosage and Administration:

MyHep (Sofosbuvir) will be prescribed for a period of 12 weeks in most cases for genotypes 1,2 and 3. For genotype 4 the treatment period is usually 24 weeks. You may be instructed differently by your doctor and should follow their advice as these are only guidelines. If you are taking ribavirin and/or pegylated interferon, these should be taken for the same length of time. It is advised to take the medicines at the same time, and to do so at the same time each day. If you take MyHep in the morning it can help to reduce associated sleeping disorders, and if you take it with food it can help reduce nausea. Sofosbuvir is usually prescribed at a dosage of 400mg. Depending on your weight, the genotype of Hepatitis C Virus that has been contracted, and other factors determined by your doctor, you may be prescribed a different dosage. Only take the dosage that has been prescribed by your doctor. Dosage could be increased to 600 mg per day depending on how treatment is progressing. Do not adjust the dosage by yourself. Your doctor will advise you if you need to adjust your dosage based on testing.

Store:

Store at 25°C in a dry place.

Side effects:

MyHep (Sofosbuvir) is well tolerated by the majority of people. It is normal to experience some queasiness and a sleeping disorder, particularly when beginning to take sufosbuvir. You can diminish the seriousness of these reactions by bringing MyHep with nourishment (for sickness) and taking your dosage in the morning (for sleep deprivation). Sofosbuvir could reduce your red blood cell count. Standard blood tests can guarantee that these levels stay inside typical points of confinement. Liver function can be affected by taking MyHep (Sofosbuvir). Any patients with a background marked by previous liver issues ought not utilize this Sofosbuvir. Liver capacity tests ought to be gone up against a standard premise while treating Hepatitis C with Sofosbuvir. In the event that you encounter serious looseness of the bowels, changes to heart rate or breathing troubles while taking sofosbuvir, let your specialist know promptly.

Precaution:

Tell your doctor of any prescription medications, over-the-counter medications, herbal treatments or nutritional supplements you tare taking. MyHep (Sofosbuvir) should not be taken alone. It ought to be taken as a major aspect of a general treatment get ready for hepatitis C more often than not likewise containing ribavirin and pegylated interferon. Try not to take Sofosbuvir while pregnant or while attempting to wind up pregnant. Sofosbuvir can bring about birth surrenders, harm to the hatchling, or early end of pregnancy. You ought to utilize mulitple types of contraception while taking this drug and for 6 months after treatment finishes to avoid pregnancy. Sofosbuvir can cause sever diarrhea in some cases. In you encounter this, make certain to keep up your liquid admission to adequate levels to forestall lack of hydration.

WARNING:

Myhep (Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Sovihep

Indication:

It is used for the treatment of hepatitis Cvirus (HCV) infection. It has been marketed since 2013. Compared to previous treatments, Sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy. Sovihep(Sofosbuvir) allows most patients to be treated successfully without the use of peginterferon, an injectable drug with severe side effects. that is a key component of older drug combinations for the treatment of HCV. Sovihep(Sofosbuvir) is used for the treatment of chronic hepatitis C, genotypes 1, 2, 3, and 4, in combination with pegylated interferon and ribavirin, or with ribavirin alone. It is also used in combination with the viral NS5a inhibitor ledipasvir in an interferon-free combination for the treatment of genotype 1 hepatitis C infection. Sovihep(Sofosbuvir) is also used in HCV patients with an HIV coinfection. The treatment is based on a number of clinical trials, for example the ELECTRON trial which showed that a dual interferon-free regimen of Sofosbuvir(Sovihep) plus ribavirin produced a 24-week post-treatment sustained virological response (SVR24) rate of 100% for previously untreated patients with HCV genotypes 2 or 3.

Brand name: Sovihep

Active Ingeridents: Sofosbuvir

Company Name: Zydus Heptiza

Package: 28 Tablets

Strength :400 mg

Mechanism of action:

Sovihep(Sofosbuvir) contains oral nucleotide analog inhibitor of the hepatitis C Virus (HCV) polymerase. The drug is a direct-acting antiviral agent and interferes straight with the HCV lifecycle, restraining the viral replication. It can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. The drug is available for oral use in the form of 400 mg tablets.

Dosage and Administration:

The recommended daily dose of Sovihep(Sofosbuvir) is 400 mg tablet to be taken once daily with or without food. Sovihep(Sofosbuvir) should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC (Chronic Hepatitis C) in adults. It is highly advisable to administer the drug under strict medical supervision and advice.

Store:

Store at 25°C in a dry place.

Side effects:

Adverse events associated with the use of Sovihep(Sofosbuvir) in combination with Ribavirin may include, but are not limited to, the following

* Fatigue, headache Adverse events associated with the use of Sovihep(Sofosbuvir) in combination with Peginterferon Alfa and Ribavirin may include, but are not limited to, the following:

* Fatigue, headache, nausea, insomnia, anemia

Precaution:

Safety and efficacy have not been established in patients younger than 18 years. Consult WARNINGS section for additional precautions.

WARNING:

Sovihep (Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Resof

Indication:

It is used for the treatment of hepatitis Cvirus (HCV) infection. It has been marketed since 2013. Compared to previous treatments, Sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy. Resof(Sofosbuvir)allows most patients to be treated successfully without the use of peginterferon, an injectable drug with severe side effects. that is a key component of older drug combinations for the treatment of HCV. Resof(Sofosbuvir)is used for the treatment of chronic hepatitis C, genotypes 1, 2, 3, and 4, in combination with pegylated interferon and ribavirin, or with ribavirin alone. It is also used in combination with the viral NS5a inhibitor ledipasvir in an interferon-free combination for the treatment of genotype 1 hepatitis C infection. Resof(Sofosbuvir)is also used in HCV patients with an HIV coinfection. The treatment is based on a number of clinical trials, for example the ELECTRON trial which showed that a dual interferon-free regimen of Sofosbuvir plus(Resof) ribavirin produced a 24-week post-treatment sustained virological response (SVR24) rate of 100% for previously untreated patients with HCV genotypes 2 or 3.

Brand name: Resof

Active Ingeridents: Sofosbuvir

Company Name:Dr.Reddy’s

Package: 28 Tablets

Strength :400 mg

Mechanism of action:

Resof(Sofosbuvir) contains oral nucleotide analog inhibitor of the hepatitis C virus (HCV) polymerase. The drug is a direct-acting antiviral agent and interferes straight with the HCV lifecycle, restraining the viral replication. It can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. The drug is available for oral use in the form of 400mg tablets.

Dosage and Administration:

The recommended daily dose of Resof(Sofosbuvir)is 400mg tablet to be taken once daily with or without food. Resof(Sofosbuvir)should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC (Chronic Hepatitis C) in adults. It is highly advisable to administer the drug under strict medical supervision and advice.

Zytiga (Abiraterone Acetate) is currently not indicated for use in women. However, if Zytiga (Abiraterone Acetate) is given to a woman, getting pregnant should be avoided and the woman should not breast feed.

Side effects:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Store:

Store Zytiga (Abiraterone Acetate) at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Zytiga (Abiraterone Acetate) out of the reach of children and away from pets.

WARNING:

Zytiga is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Sofocure

Indication:

It is used for the treatment of hepatitis Cvirus (HCV) infection. It has been marketed since 2013. Compared to previous treatments, Sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy. Sofocure (Sofosbuvir) allows most patients to be treated successfully without the use of peginterferon, an injectable drug with severe side effects. that is a key component of older drug combinations for the treatment of HCV.
Sofocure (Sofosbuvir) is used for the treatment of chronic hepatitis C, genotypes 1, 2, 3, and 4, in combination with pegylated interferon and ribavirin, or with ribavirin alone. It is also used in combination with the viral NS5a inhibitor ledipasvir in an interferon-free combination for the treatment of genotype 1 hepatitis C infection. Sofocure (Sofosbuvir) is also used in HCV patients with an HIV coinfection. The treatment is based on a number of clinical trials, for example the ELECTRON trial which showed that a dual interferon-free regimen of Sofocure (Sofosbuvir) plus ribavirin produced a 24-week post-treatment sustained virological response (SVR24) rate of 100% for previously untreated patients with HCV genotypes 2 or 3.

Brand name: Sofocure

Active Ingeridents: Sofosbuvir

Company Name:Emcure

Package: 28 Tablet 28 Tablets

Strength :400 mg

Mechanism of action:

Sofocure (Sofosbuvir) contains oral nucleotide analog inhibitor of the hepatitis C virus (HCV) polymerase. The drug is a direct-acting antiviral agent and interferes straight with the HCV lifecycle, restraining the viral replication. It can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. The drug is available for oral use in the form of 400mg tablets.

Dosage and Administration:

The recommended daily dose of Sofocure (Sofosbuvir) is 400mg tablet to be taken once daily with or without food. Sofocure (Sofosbuvir) should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC (Chronic Hepatitis C) in adults. It is highly advisable to administer the drug under strict medical supervision and advice.

Precaution:

Safety and efficacy have not been established in patients younger than 18 years. Consult WARNINGS section for additional precautions.

Side effects:

Adverse events associated with the use of Sofocure (Sofosbuvir) in combination with Ribavirin may include, but are not limited to, the following

Fatigue , headache
Adverse events associated with the use of Sofocure (Sofosbuvir) in combination with Peginterferon Alfa and Ribavirin may include, but are not limited to, the following:

Fatigue,headache, nausea, insomnia, anemia

Store:

Store at 25°C in a dry place.

WARNING:

Sofocure (Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Hepcvir

Indication:

It is used for the treatment of hepatitis Cvirus (HCV) infection. It has been marketed since 2013. Compared to previous treatments, Sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy. Hepcvir (Sofosbuvir) allows most patients to be treated successfully without the use of peginterferon, an injectable drug with severe side effects. that is a key component of older drug combinations for the treatment of HCV.
Hepcvir (Sofosbuvir) is used for the treatment of chronic hepatitis C, genotypes 1, 2, 3, and 4, in combination with pegylated interferon and ribavirin, or with ribavirin alone. It is also used in combination with the viral NS5a inhibitor ledipasvir in an interferon-free combination for the treatment of genotype 1 hepatitis C infection. Hepcvir (Sofosbuvir) is also used in HCV patients with an HIV coinfection. The treatment is based on a number of clinical trials, for example the ELECTRON trial which showed that a dual interferon-free regimen of Hepcvir (Sofosbuvir) plus ribavirin produced a 24-week post-treatment sustained virological response (SVR24) rate of 100% for previously untreated patients with HCV genotypes 2 or 3.

Brand name: Hepcvir

Active Ingeridents: Sofosbuvir

Company Name:Cipla

Package: 15 Tablets

Strength :400 mg

Mechanism of action:

Hepcvir (Sofosbuvir) contains oral nucleotide analog inhibitor of the hepatitis C virus (HCV) polymerase. The drug is a direct-acting antiviral agent and interferes straight with the HCV lifecycle, restraining the viral replication. It can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. The drug is available for oral use in the form of 400mg tablets.

Dosage and Administration:

The recommended daily dose of Hepcvir (Sofosbuvir) is 400mg tablet to be taken once daily with or without food. Hepcvir (Sofosbuvir) should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC (Chronic Hepatitis C) in adults. It is highly advisable to administer the drug under strict medical supervision and advice.

Precaution:

Safety and efficacy have not been established in patients younger than 18 years. Consult WARNINGS section for additional precautions.

Side effects:

Adverse events associated with the use of Hepcvir (Sofosbuvir) in combination with Ribavirin may include, but are not limited to, the following

Fatigue , headache
Adverse events associated with the use of Hepcvir (Sofosbuvir) in combination with Peginterferon Alfa and Ribavirin may include, but are not limited to, the following:

Fatigue,headache, nausea, insomnia, anemia

Store:

Store at 25°C in a dry place.

WARNING:

Hepcvir (Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Viroclear

Indication:

It is used for the treatment of hepatitis Cvirus (HCV) infection. It has been marketed since 2013. Compared to previous treatments, Sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy. Viroclear (Sofosbuvir) allows most patients to be treated successfully without the use of peginterferon, an injectable drug with severe side effects. that is a key component of older drug combinations for the treatment of HCV.
Viroclear (Sofosbuvir) is used for the treatment of chronic hepatitis C, genotypes 1, 2, 3, and 4, in combination with pegylated interferon and ribavirin, or with ribavirin alone. It is also used in combination with the viral NS5a inhibitor ledipasvir in an interferon-free combination for the treatment of genotype 1 hepatitis C infection. Viroclear (Sofosbuvir) is also used in HCV patients with an HIV coinfection. The treatment is based on a number of clinical trials, for example the ELECTRON trial which showed that a dual interferon-free regimen of Viroclear (Sofosbuvir) plus ribavirin produced a 24-week post-treatment sustained virological response (SVR24) rate of 100% for previously untreated patients with HCV genotypes 2 or 3.

Brand name: Viroclear

Active Ingeridents: Sofosbuvir

Company Name:Abbott

Package: 28 Tablets

Strength :400 mg

Mechanism of action:

Viroclear (Sofosbuvir) contains oral nucleotide analog inhibitor of the hepatitis C virus (HCV) polymerase. The drug is a direct-acting antiviral agent and interferes straight with the HCV lifecycle, restraining the viral replication. It can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. The drug is available for oral use in the form of 400mg tablets.

Dosage and Administration:

The recommended daily dose of Viroclear (Sofosbuvir) is 400mg tablet to be taken once daily with or without food. Viroclear (Sofosbuvir) should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC (Chronic Hepatitis C) in adults. It is highly advisable to administer the drug under strict medical supervision and advice.

Precaution:

Safety and efficacy have not been established in patients younger than 18 years. Consult WARNINGS section for additional precautions.

Side effects:

Adverse events associated with the use of Viroclear (Sofosbuvir) in combination with Ribavirin may include, but are not limited to, the following

Fatigue , headache
Adverse events associated with the use of Viroclear (Sofosbuvir) in combination with Peginterferon Alfa and Ribavirin may include, but are not limited to, the following:

Fatigue,headache, nausea, insomnia, anemia

Store:

Store at 25°C in a dry place.

WARNING:

Viroclear (Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Novisof

Indication:

It is used for the treatment of hepatitis Cvirus (HCV) infection. It has been marketed since 2013. Compared to previous treatments, Sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy. Novisof (Sofosbuvir) allows most patients to be treated successfully without the use of peginterferon, an injectable drug with severe side effects. that is a key component of older drug combinations for the treatment of HCV.
Novisof (Sofosbuvir) is used for the treatment of chronic hepatitis C, genotypes 1, 2, 3, and 4, in combination with pegylated interferon and ribavirin, or with ribavirin alone. It is also used in combination with the viral NS5a inhibitor ledipasvir in an interferon-free combination for the treatment of genotype 1 hepatitis C infection. Novisof (Sofosbuvir) is also used in HCV patients with an HIV coinfection. The treatment is based on a number of clinical trials, for example the ELECTRON trial which showed that a dual interferon-free regimen of Novisof (Sofosbuvir) plus ribavirin produced a 24-week post-treatment sustained virological response (SVR24) rate of 100% for previously untreated patients with HCV genotypes 2 or 3.

Brand name: Novisof

Active Ingeridents: Sofosbuvir

Company Name:Wockhardt

Package: 28 Tablets

Strength :400 mg

Mechanism of action:

Novisof (Sofosbuvir) contains oral nucleotide analog inhibitor of the hepatitis C virus (HCV) polymerase. The drug is a direct-acting antiviral agent and interferes straight with the HCV lifecycle, restraining the viral replication. It can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. The drug is available for oral use in the form of 400mg tablets.

Dosage and Administration:

The recommended daily dose of Novisof (Sofosbuvir) is 400mg tablet to be taken once daily with or without food. Novisof (Sofosbuvir) should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC (Chronic Hepatitis C) in adults. It is highly advisable to administer the drug under strict medical supervision and advice.

Precaution:

Safety and efficacy have not been established in patients younger than 18 years. Consult WARNINGS section for additional precautions.

Side effects:

Adverse events associated with the use of Novisof (Sofosbuvir) in combination with Ribavirin may include, but are not limited to, the following

Fatigue , headache
Adverse events associated with the use of Novisof (Sofosbuvir) in combination with Peginterferon Alfa and Ribavirin may include, but are not limited to, the following:

Fatigue,headache, nausea, insomnia, anemia

Store:

Store at 25°C in a dry place.

WARNING:

Novisof (Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Sofab

Indication:

It is used for the treatment of hepatitis Cvirus (HCV) infection. It has been marketed since 2013. Compared to previous treatments, Sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy. Sofab (Sofosbuvir) allows most patients to be treated successfully without the use of peginterferon, an injectable drug with severe side effects. that is a key component of older drug combinations for the treatment of HCV.
Sofab (Sofosbuvir) is used for the treatment of chronic hepatitis C, genotypes 1, 2, 3, and 4, in combination with pegylated interferon and ribavirin, or with ribavirin alone. It is also used in combination with the viral NS5a inhibitor ledipasvir in an interferon-free combination for the treatment of genotype 1 hepatitis C infection. Sofab (Sofosbuvir) is also used in HCV patients with an HIV coinfection. The treatment is based on a number of clinical trials, for example the ELECTRON trial which showed that a dual interferon-free regimen of Sofab (Sofosbuvir) plus ribavirin produced a 24-week post-treatment sustained virological response (SVR24) rate of 100% for previously untreated patients with HCV genotypes 2 or 3.

Brand name: Sofab

Active Ingeridents: Sofosbuvir

Company Name:Ranbaxy

Package: 28 Tablets

Strength :400 mg

Mechanism of action:

Sofab (Sofosbuvir) contains oral nucleotide analog inhibitor of the hepatitis C virus (HCV) polymerase. The drug is a direct-acting antiviral agent and interferes straight with the HCV lifecycle, restraining the viral replication. It can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. The drug is available for oral use in the form of 400mg tablets.

Dosage and Administration:

The recommended daily dose of Sofab (Sofosbuvir) is 400mg tablet to be taken once daily with or without food. Sofab (Sofosbuvir) should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC (Chronic Hepatitis C) in adults. It is highly advisable to administer the drug under strict medical supervision and advice.

Precaution:

Safety and efficacy have not been established in patients younger than 18 years. Consult WARNINGS section for additional precautions.

Side effects:

Adverse events associated with the use of Sofab (Sofosbuvir) in combination with Ribavirin may include, but are not limited to, the following

Fatigue , headache
Adverse events associated with the use of Sofab (Sofosbuvir) in combination with Peginterferon Alfa and Ribavirin may include, but are not limited to, the following:

Fatigue,headache, nausea, insomnia, anemia

Store:

Store at 25°C in a dry place.

WARNING:

Sofab (Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Cimivir

Indication:

It is used for the treatment of hepatitis Cvirus (HCV) infection. It has been marketed since 2013. Compared to previous treatments, Sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy. Cimivir (Sofosbuvir) allows most patients to be treated successfully without the use of peginterferon, an injectable drug with severe side effects. that is a key component of older drug combinations for the treatment of HCV.
Cimivir (Sofosbuvir) is used for the treatment of chronic hepatitis C, genotypes 1, 2, 3, and 4, in combination with pegylated interferon and ribavirin, or with ribavirin alone. It is also used in combination with the viral NS5a inhibitor ledipasvir in an interferon-free combination for the treatment of genotype 1 hepatitis C infection. Cimivir (Sofosbuvir) is also used in HCV patients with an HIV coinfection. The treatment is based on a number of clinical trials, for example the ELECTRON trial which showed that a dual interferon-free regimen of Cimivir (Sofosbuvir) plus ribavirin produced a 24-week post-treatment sustained virological response (SVR24) rate of 100% for previously untreated patients with HCV genotypes 2 or 3.

Brand name: Cimivir

Active Ingeridents: Sofosbuvir

Company Name:Biocon

Package: 28 Tablets

Strength :400 mg

Mechanism of action:

Cimivir (Sofosbuvir) contains oral nucleotide analog inhibitor of the hepatitis C virus (HCV) polymerase. The drug is a direct-acting antiviral agent and interferes straight with the HCV lifecycle, restraining the viral replication. It can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. The drug is available for oral use in the form of 400mg tablets.

Dosage and Administration:

The recommended daily dose of Cimivir (Sofosbuvir) is 400mg tablet to be taken once daily with or without food. Cimivir (Sofosbuvir) should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC (Chronic Hepatitis C) in adults. It is highly advisable to administer the drug under strict medical supervision and advice.

Precaution:

Safety and efficacy have not been established in patients younger than 18 years. Consult WARNINGS section for additional precautions.

Side effects:

Adverse events associated with the use of Cimivir (Sofosbuvir) in combination with Ribavirin may include, but are not limited to, the following

Fatigue , headache
Adverse events associated with the use of Cimivir (Sofosbuvir) in combination with Peginterferon Alfa and Ribavirin may include, but are not limited to, the following:

Fatigue,headache, nausea, insomnia, anemia

Store:

Store at 25°C in a dry place.

WARNING:

Cimivir (Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Virso

Indication:

It is used for the treatment of hepatitis Cvirus (HCV) infection. Compared to previous treatments, sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy. Sofosbuvir allows most patients to be treated successfully without the use of peginterferon, an injectable drug with severe side effects. that is a key component of older drug combinations for the treatment of HCV.

Brand name: Virso

Active Ingeridents: Sofosbuvir

Company Name:Sofosbuvir

Package: 28 Tablets/Bottle

Strength :400 mg

Mechanism of action:

Sofosbuvir contains oral nucleotide analog inhibitor of the hepatitis C virus (HCV) polymerase. The drug is a direct-acting antiviral agent and interferes straight with the HCV lifecycle, restraining the viral replication. It can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. The drug is available for oral use in the form of 400mg tablets.

Dosage and Administration:

The recommended daily dose of Sofosbuvir is 400mg tablet to be taken once daily with or without food. Sofosbuvir should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC (Chronic Hepatitis C) in adults. It is highly advisable to administer the drug under strict medical supervision and advice.

Precaution:

Safety and efficacy have not been established in patients younger than 18 years. Consult WARNINGS section for additional precautions.

Side effects:

Adverse events associated with the use of Sofosbuvir in combination with Ribavirin may include, but are not limited to, the following

Fatigue , headache
Adverse events associated with the use of Sofosbuvir in combination with Peginterferon Alfa and Ribavirin may include, but are not limited to, the following:

Fatigue,headache, nausea, insomnia, anemia

Store:

Store at 25°C in a dry place.

WARNING:

Virso (Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.